- Home
- LNKB vs SERA Comparison
LNKB vs SERA Comparison
Compare LNKB & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNKB | SERA |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.5M | 75.2M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LNKB | SERA |
|---|---|---|
| Price | $8.68 | $2.12 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 423.6K | 60.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | 26.76 | ★ 32.32 |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $186,504,000.00 | $81,000.00 |
| Revenue This Year | $10.18 | $554.81 |
| Revenue Next Year | $9.33 | $517.27 |
| P/E Ratio | $9.66 | ★ N/A |
| Revenue Growth | ★ 11.29 | 5.19 |
| 52 Week Low | $6.57 | $1.37 |
| 52 Week High | $9.59 | $4.09 |
Technical Indicators
Market Signals| Indicator | LNKB | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 61.27 |
| Support Level | $8.44 | $1.67 |
| Resistance Level | $9.03 | $2.41 |
| Average True Range (ATR) | 0.17 | 0.24 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 38.26 | 77.79 |
Price Performance
Historical ComparisonAbout LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.